Meet The FDA’s First Chief Scientist
4 CommentsBy Ed Silverman // April 9th, 2008 // 11:25 am
His name is Frank Torti, he has brand-name credentials - Harvard, Johns Hopkins, Stanford - and he is currently director of the comprehensive care center at Wake Forest University’s School of Medicine in Winston-Salem, North Carolina.
What will he do at the FDA? In a statement, FDA commish Andy von Eschenbach notes the new position stems from the Food and Drug Administration Amendments Act of 2007. So Torti will help launch an FDA Fellowship program, which Andy hopes will attract up to 2,000 professionals for a two-year training program. Torti will also spend his time minding the agency’s “intramural research programs,” with an emphasis on clinical trials. As usual, Andy wasn’t terribly specific.
You can read more about Torti here.
University Update - Wake Forest University - Meet The FDA’s First Chief Scientist
[...] Tech Meet The FDA’s First Chief Scientist » This Summary is from an article posted at Pharmalot » News, Comment and Conversation on [...]
Justice in Michigan
I am applying. I am not that kind of scientist, but I am an expert in shmooze remediation.
LILLI
For the past hour I have been researching about Dr. Frank Tori and did not find any current legimate information that would give me confidence in his achievments at Wake Forrest. At this point my horrible experiences with doctors, medicdal care, healthcare industries, hospitals, pharmaceuticals, and our federal and state government legislature does not guarantee that FDA’s first chief Scientist will help thye public, as usual it will only help the medical profession, pharamceuticals, healthcae industries, hospitals and the lobbyists that influence congress.
pg
On the brighter side Lilli, when looking at research and publications connected to Frank M Tori cancer studies there are some that show his relationship to research on various vitamins and their effect on cancers.
That could mean that he isn’t quite as ‘industry-led’ as some and might be more critical while he’s ‘minding the intramural research programs with an emphasis on clinical trials’. Not all is lost. Not yet.